Neel Heerasing

Neel Heerasing

Auto-generated profile, based on publicly available information

Neel Heerasing

Department of Gastroenterology Barwon Health Geelong Victoria Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
NHN. Heerasing
N. Heerasing
BTB. Thompson
B. Thompson
PHP. Hendy
P. Hendy
GHG. A. Heap
G. A. Heap
GWG. Walker
G. Walker
JGJ. R. Goodhand
J. R. Goodhand
Summary: Background: Few studies have reported the systematic use of exclusive enteral nutrition in the perioperative setting.Aim: To test the hypothesis that exclusive enteral nutrition provides a safe and effective bridge to surgery and reduces post‐operative complications, in adult patients with Crohn's disease requiring urgent surgery for stricturing or penetrating complications.Methods: Patients treated with exclusive enteral nutrition prior to surgery were each matched with two control patients for disease behaviour, type of surgery, age at diagnosis and disease duration. Data on disease phenotype, nutritional status, operative course and post‐operative complications were obtained.Results: Twenty‐five per cent [13/51] patients treated with exclusive enteral nutrition avoided surgery. Exclusive enteral nutrition had no effect on pre‐operative weight, but it significantly reduced serum CRP [median at baseline 36 (interquartile range, IQR: 13–91] vs. pre‐operation 8 (4–31) mg/L, P = 0.02]. The median (IQR) length of surgery was shorter in patients pre‐optimised with exclusive enteral nutrition than controls [3.0 (2.5–3.5) vs. 3.5 (3.0–4.0) hours respectively, P < 0.001]. Multivariable logistic regression analysis confirmed that going straight‐to‐surgery compared exclusive enteral nutrition pre‐optimisation was associated with a ninefold increase in the incidence of post‐operative abscess and/or anastomotic leak [OR 9.1; 95% CI (1.2–71.2), P = 0.04].Conclusions: Exclusive enteral nutrition frequently down‐stages the need for surgery in patients presenting with stricturing or penetrating complications of Crohn's disease; it is associated with a reduction in systemic inflammation, operative times and the incidence of post‐operative abscess or anastomotic leak. Further trials are needed to elucidate how exclusive enteral nutrition may improve operative outcomes.

26 May 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
AAAysha H. Al‐Ani
Aysha H. Al‐Ani
RPRalley E. Prentice
Ralley E. Prentice
CRClarissa A. Rentsch
Clarissa A. Rentsch
DJDoug Johnson
Doug Johnson
ZAZaid Ardalan
Zaid Ardalan
BCBritt Christensen
Britt Christensen

5 March 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GWG. J. Walker
G. J. Walker
LML. Moore
L. Moore
NHN. Heerasing
N. Heerasing
PHP. Hendy
P. Hendy
MPM. H. Perry
M. H. Perry
TAT. Ahmad
T. Ahmad
Summary: Background: Primary care faecal calprotectin testing distinguishes inflammatory bowel disease (IBD) from functional gut disorder in young patients presenting with abdominal symptoms; however, previous evaluations have excluded patients with alarm symptoms.Aims: We sought to evaluate the diagnostic accuracy of calprotectin to distinguish IBD from functional gut disorder in young adults in whom general practitioners (GPs) suspected IBD; including patients reporting gastrointestinal alarm symptoms. We hypothesised that calprotectin would reduce secondary care referrals and healthcare costs.Methods: We undertook a prospective cohort study of 789 young adults (18‐46 years old) presenting with gastrointestinal symptoms to 49 local general practices that had undergone calprotectin testing (1053 tests: between Jan 2014 and May 2016) because of suspected IBD. We considered calprotectin levels of ≥100 μg/g positive. Primary and secondary care records over 12 months from the point of calprotectin testing were used as the reference standard.Results: Overall, 39% (308/789) patients reported gastrointestinal alarm symptoms and 6% (50/789) tested patients were diagnosed with IBD. The positive and negative predictive values of calprotectin testing for distinguishing IBD from functional gut disorder in patients with gastrointestinal alarm symptoms were 50% (95% CI 36%‐64%) and 98% (96%‐100%): and in patients without gastrointestinal alarm symptoms were 27% (16%‐41%) and 99% (98%‐100%), respectively. We estimate savings of 279 referrals and £160 per patient.Conclusions: Calprotectin testing of young adults with suspected IBD in primary care accurately distinguishes IBD from functional gut disorder, even in patients with gastrointestinal alarm symptoms and reduces secondary care referrals and diagnostic healthcare costs.

23 June 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GWGareth J. Walker
Gareth J. Walker
SLSimeng Lin
Simeng Lin
NCNeil Chanchlani
Neil Chanchlani
ATAmanda Thomas
Amanda Thomas
PHPeter Hendy
Peter Hendy
JGJames R. Goodhand
James R. Goodhand
Summary: Background: Delay in the diagnosis of inflammatory bowel disease (IBD) is common and contemporary UK studies are lacking.Aim: To determine factors associated with, and the consequences of, a prolonged time to diagnosis in IBD.Methods: This quality improvement study included 304 adults with a new IBD diagnosis made between January 2014 and December 2017 across 49 general practices (GP) and gastroenterology secondary care services. Outcome measures were demographic, clinical and laboratory factors associated with a delayed time, defined as greater than upper quartile, to: (a) patient presentation (b) GP referral (c) secondary care diagnosis, and factors associated with a complicated disease course (hospitalisation and/or surgery and/or biologic treatment) in the year after diagnosis.Results: The median [IQR] diagnosis sub‐intervals were: (a) patient = 2.1 months [0.9‐5.1]; (b) GP = 0.3 months [0.0‐0.9]; (c) secondary care = 1.1 months [0.5‐2.1]. 50% of patients were diagnosed within 4 months and 92% were diagnosed within 2 years of symptom onset. Diagnostic delay was more common in Crohn's disease (7.6 months [3.1‐15.0]) than ulcerative colitis (3.3 months [1.9‐7.3]) (P < 0.001). Patients who presented as an emergency (P < 0.001) but not those with a delayed overall time to diagnosis (P = 0.35) were more likely to have a complicated disease course.Conclusion: Time to patient presentation is the largest component of time to IBD diagnosis. Emergency presentation is common and, unlike a delayed time to diagnosis, is associated with a complicated disease course.

24 June 2020 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
BHBen Hamilton
Ben Hamilton
HGHarry Green
Harry Green
NHNeel Heerasing
Neel Heerasing
PHPeter Hendy
Peter Hendy
LMLucy Moore
Lucy Moore
JGJames Goodhand
James Goodhand
Background and aims We sought to define temporal changes in prevalence of inflammatory bowel disease (IBD) in East Devon, UK, in order to facilitate service planning over the next 5 years. Methods Multiple primary and secondary care databases were used to identify and verify cases. Point prevalence and incidence of IBD were reported in April 2017 and from 2008 to 2016, respectively. Future prevalence and healthcare activity requirements were estimated by linear regression. Results Prevalence of ulcerative colitis (UC), Crohn’s disease (CD) and inflammatory bowel disease unclassified (IBDU) were 479.72, 265.94 and 35.34 per 100 000 persons, respectively. In 2016, the incidence rates of UC, CD and IBDU were 15.4, 10.7 and 1.4 per 100 000 persons per year, respectively. There were no significant changes in the incidence of CD (p=0.49, R=0.26) or UC (p=0.80, R=0.10). IBD prevalence has increased by 39.9% (95% CI 28.2 to 53.7) in the last 10 years without differences in the rate of change between UC and CD. Overall, 27% of patients were managed in primary care, a quarter of whom were eligible but not receiving endoscopic surveillance. Outpatient clinics, MRI and biologic use, but not helpline calls, admissions, or surgeries increased over and above the change in IBD prevalence. Conclusions We report one of the highest prevalence and incidence rates of IBD from Northern Europe. Overall, IBD incidence is static, but prevalence is increasing. We estimate that 1% of our population will live with IBD between 2025 and 2030.

18 May 2020 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
GWGareth J Walker
Gareth J Walker
NCNeil Chanchlani
Neil Chanchlani
ATAmanda Thomas
Amanda Thomas
SLSimeng Lin
Simeng Lin
LMLucy Moore
Lucy Moore
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
Objective To determine the diagnostic accuracy of calprotectin to diagnose inflammatory bowel disease (IBD) in children in whom general practitioners (GPs) suspected IBD. Design Prospective observational cohort study of a new calprotectin-based primary care referral pathway. Setting 48 GP practices and gastroenterology secondary care services at the Royal Devon and Exeter NHS Foundation Trust in the South-West of England, UK. Patients 195 children aged between 4 and 18 years referred on the pathway between January 2014 and August 2017 for investigation of gastrointestinal symptoms were included. Interventions Primary-care-driven faecal calprotectin testing. Primary and secondary care records over 12 months from the point of calprotectin testing were used as the reference standard. Main outcome measures Diagnostic accuracy of calprotectin testing to detect IBD. Results 7% (13/195) tested patients were diagnosed with IBD. Using our prespecified cut-off of 100 µg/g, calprotectin had a diagnostic accuracy of 91% (95% CI 86% to 95%) with a sensitivity for distinguishing IBD from non-IBD of 100% (95% CI 75% to 100%), a specificity of 91% (95% CI 85% to 94%), a positive predictive value of 43% (95% CI 25% to 63%) and a negative predictive value of 100% (95% CI 98% to 100%). Calprotectin testing had no effect on the time to diagnosis, but a negative test contributed to saved referrals and was associated with fewer diagnostic tests in secondary care. Conclusions Calprotectin testing of children with suspected IBD in primary care accurately distinguishes IBD from a functional gut disorder, reduces secondary care referrals and associated diagnostic healthcare utilisation.